Better Buy: Dynavax Technologies Corp. vs. Geron Corp.

Dynavax Technologies Corp. and Geron Corp. have pending catalysts that could cause their shares to double from current levels. Here's a Foolish look at which company offers the better risk-to-reward profile.

Jul 4, 2014 at 7:50AM

Beaten-down biotechs have an odd way of making heroic comebacks. But to catch lightning in a bottle by bottom feeding in the biotech arena, you need to understand why the company's share price cratered in the first place -- and what needs to unfold for the stock to come roaring back,

Dynavax Technologies (NASDAQ:DVAX) and Geron (NASDAQ:GERN) are two small-cap biotechs that have fallen on hard times due to regulatory issues surrounding their flagship clinical candidates. And although both companies have rebounded since their dramatic declines, they are still trading well below their former highs. With this in mind, let's consider which company has the better chance of regaining its former market share going forward. 

GERN Chart

GERN data by YCharts

Dynavax's hepatitis B vaccine could spark a comeback
Dynavax's share price cratered last year after the Food and Drug Administration requested additional clinical trial data to more thoroughly explore the safety profile of Heplisav, the company's experimental hepatitis B vaccine. Although a late-stage trial showed that the vaccine is more effective in a broader array of patient populations than GlaxoSmithKline's (NYSE:GSK) Engerix-B, the study wasn't sufficiently powered to detect rare but serious side effects. 

Dynavax has since initiated a new late-stage trial that will both provide further insight into Heplisav's safety profile and investigate the vaccine's efficacy in type 2 diabetics. This trial is expected to conclude in late 2015 -- putting it on track for new regulatory filings in both the U.S. and EU by early 2016. With a commercial opportunity that is projected to hover around $700 million per year in peak sales, Dynavax looks undervalued at its current market cap of $415 million.

Geron's troubled blood cancer drug might ignite a rally
After a tumultuous history of clinical trials with a handful of potentially revolutionary new medicines, Geron's new management has decided to focus squarely on developing imetelstat as a treatment for a diversity of blood-based cancers. So far, imetelstat has shown impressive efficacy results as a treatment for myelofibrosis, with some patients even going into complete remission.

What's noteworthy about this result is that the only approved drug for myelofibrosis, Incyte's (NASDAQ:INCY) Jakafi, does not result in disease remission, meaning that imetelstat could be a breakthrough therapy for this difficult to treat disease. 

Even so, imetelstat has showed some worrisome signs of increasing the risk of liver toxicity in its ongoing clinical trials -- leading the FDA to place a clinical hold on the drug last March and causing shares to plummet by over 50% in a single day.

Since then, the agency has lifted the partial hold for the myelofibrosis trial, but it remains in place for other indications such as essential thrombocythemia, polycythemia vera, and multiple myeloma. The company also cannot initiate any new clinical trials for the drug until this issue is resolved. 

Going forward, Geron is required to perform additional preclinical studies to clarify imetelstat's safety profile before the full hold can be released. While some investors are arguing that the agency will release the hold sooner rather than later, it's important to understand that these new studies won't be completed for at least a few months, if not longer.

Foolish wrap-up
Clinical trials are inherently risks, given that something goes wrong more often than not. So, there is a real chance that neither one of these companies will reach and/or surpass their former glory.

That being said, I am cautiously optimistic that Dynavax will ultimately see Heplisav through to an approval. My belief is based on the fact that no major red flags popped up in the clinical trial data thus far that would suggest it will turn out to be unsafe -- or at least its benefits won't outweigh the risks in certain difficult to treat subpopulations.

By contrast, imetelstat's safety profile has proven to be a real concern, leading to the clinical hold in the first place. Perhaps the ongoing preclinical studies will warrant lifting imetelstat's hold for other indications, but Heplisav looks like the safer bet, in my opinion. And given that the potential upside for each stock looks roughly similar, I think Dynavax is a better speculative buy in this case.  

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

  

George Budwell owns shares of Dynavax Technologies. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers